Thalidomide and dexamethasone in newly diagnosed multiple myeloma.

被引：0
|
作者：
McHugh, Johnny [1 ]
O'Ceallaigh, Cathal [1 ]
Keane, Colm [1 ]
Otridge, Brian W. [1 ]
O'Gorman, Peter [1 ]
机构：
[1] Mater Misericordiae Univ Hosp, Dept Haematol, Dublin, Ireland
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5120
引用
收藏
页码：370B / 370B
页数：1
相关论文
共 50 条
  • [41] Bortezomib, dexamethasone plus thalidomide for treatment of newly diagnosed multiple myeloma patients with or without renal impairment
    Guangzhong Yang
    Wenming Chen
    Yin Wu
    Chinese Journal of Cancer Research, 2013, 25 (02) : 155 - 160
  • [42] Thalidomide plus dexamethasone for untreated newly diagnosed multiple myeloma patients and deep vein thrombosis.
    Jimenez, Victor H.
    Dominguez, Virginia J.
    Reynoso, Eduardo E.
    BLOOD, 2006, 108 (11) : 362B - 362B
  • [43] Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone
    Tosi, Patrizia
    Zamagni, Elena
    Cangini, Delia
    Tacchetti, Paola
    Di Raimondo, Francesco
    Catalano, Lucio
    D'Arco, Alfonso
    Ronconi, Sonia
    Cellini, Claudia
    Offidani, Massimo
    Perrone, Giulia
    Ceccolini, Michela
    Brioli, Annamaria
    Tura, Sante
    Baccarani, Michele
    Cavo, Michele
    BLOOD, 2006, 108 (12) : 3951 - 3952
  • [44] Higher single dose of bortezomib plus thalidomide and dexamethasone is a promising therapy for newly diagnosed multiple myeloma
    Xu, Peipei
    Zhou, Rongfu
    Xu, Jingyan
    Ouyang, Jian
    Shao, Xiaoyan
    Chen, Bing
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 (05) : 2099 - 2106
  • [45] Bortezomib, dexamethasone plus thalidomide for treatment of newly diagnosed multiple myeloma patients with or without renal impairment
    Yang, Guangzhong
    Chen, Wenming
    Wu, Yin
    CHINESE JOURNAL OF CANCER RESEARCH, 2013, 25 (02) : 155 - 160
  • [46] Coagulation profiles and thromboembolic events of bortezomib plus thalidomide and dexamethasone therapy in newly diagnosed multiple myeloma
    Shen, Yunfeng
    Zhou, Xin
    Wang, Zhi
    Yang, Guohua
    Jiang, Yuanqiang
    Sun, Chao
    Wang, Jing
    Tong, Yi
    Guo, Hongfeng
    LEUKEMIA RESEARCH, 2011, 35 (02) : 147 - 151
  • [47] Phase II Trial of Syncopated Thalidomide, Lenalidomide, and Weekly Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
    Tufail, Madiha
    Siegel, David S.
    McBride, Laura
    Bilotti, Elizabeth
    Bello, Erica
    Anand, Palka
    Olivo, Karly
    Bendarz, Urszula
    McNeill, Ann
    Vesole, David H.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2012, 12 (03): : 186 - 190
  • [48] Superior complete remission/very good partial remission rate with peri-transplant administration of thalidomide-dexamethasone for newly diagnosed multiple myeloma.
    Cavo, M
    Zamagni, E
    Tosi, P
    Cangini, D
    Tacchetti, P
    Cellini, C
    Testoni, N
    Nicci, C
    de Vivo, A
    Perrone, G
    Ceccolini, M
    Baccarani, M
    BLOOD, 2005, 106 (11) : 456B - 456B
  • [49] Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma
    Laubach, Jacob P.
    Schlossman, Robert L.
    Mitsiades, Constantine S.
    Anderson, Kenneth C.
    Richardson, Paul G.
    EXPERT REVIEW OF HEMATOLOGY, 2011, 4 (01) : 51 - 60
  • [50] Combined analysis of British and German trials with oral idarubicin and dexamethasone in patients with newly diagnosed multiple myeloma.
    Glasmacher, A
    Cook, G
    Schmidt-Wolf, IG
    Goldschmidt, H
    BLOOD, 2003, 102 (11) : 451A - 451A
12345